Search Results

It is always ligand × system. In the full lecture, Dr. True receptor selectivity must transcend the cell line. A “silent” ligand may be system-limited. More often, one ligand is partial. Now EC₅₀ values alone are insufficient. Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity

What feels like momentum can quietly become dilution. More programs. Broader roadmaps. What Strategic Discipline Actually Looks Like in Practice Strategic discipline does not mean shrinking look for ambition that is ambitious but engineered. ✅ In other words, strategic discipline does not limit If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention

👉 In early-stage biotech, activity often feels like strategy. On the surface, this looks like a strength. There is movement across the board. Capital is limited. Leadership attention is stretched. Internally, this feels like diversification. Letting go of a program can feel like abandoning potential value.

action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem

. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting failure.

This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly Legacy courses will migrate into this format over the coming weeks, with live courses returning in March What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST.

In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold The pressure mounts further as regulators require detection and characterization of these liabilities—even Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery

Latest breakthroughs :  Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition Listeners will gain perspective on: Assay choice as strategy , not convenience. Leadership decisions  that keep multidisciplinary teams aligned. 👉 Listen to the full conversation ➤

Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue Drug-Like Properties: The Real Starting Point PK does not begin at dosing—it begins with physicochemical Transporter affinity and solubility limits routinely sabotage otherwise strong ligands Effective PK Kenakin introduces mass-balance thinking and metabolic accounting  to proactively manage liabilities your fingertips : Explore the full library ➤

They emphasize different elements depending on who is listening, which creates confusion instead of clarity This puts the burden of synthesis on the listener , who may not share the same context or priorities. External conversations become easier because the listener understands what they are being asked to evaluate When that decision is made explicitly, depth stops being a liability. They respond to questions as they arise, adjusting emphasis depending on who is listening.

If you have ever wondered why effort does not always translate into results, the answer often lives much Tradeoffs have already been accepted. 👉 What looks like a performance gap late in the year is often What once felt like optionality quietly turns into constraint. This is the phase where choices feel lightweight, but their impact is anything but. With alignment, execution starts to feel lighter, faster, and more coherent.

. 👉 Strong resumes feel like protection against uncertainty. What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize In teams working on complex biology like GPCR targets, this kind of drift is not unusual. matter in early-stage biotech environments. 1️⃣ How candidates describe moments without clear answers: Listen

Complexity feels like progress. At this stage, failure does not look like failure. It looks like motion. Additional data feels like risk reduction, even when it does not change the strategic picture. Teams are no longer sure what success looks like. 👉 No single decision breaks the company, but the absence business reality. ✅ At its core, this is what a functional strategy provides: 1️⃣ Clear priorities that limit

Slides list filings and dates, but do not explain how those rights support the fundraising narrative control that feel unclear or constrained This gap appears most often in academic spinouts, but it is not limited Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights Founders are expected to show awareness of constraints and options ✅ Looking toward 2026, this trend is likely They can explain what the IP protects, where its limits are, and how that fits the company's direction

. 👉 What it usually looks like: Weekly priorities shift based on whoever raised the loudest concern. That’s the danger. 👉 From the inside, however, it creates a quiet drift: lots of activity, little compounding investor messaging drifts Timelines become aspirational rather than operational ✅ What “good” looks like teams working with partial context narrative inconsistency across stakeholders ✅ What “good” looks like , not momentum Scientific surprises hit harder because the system has no buffer ✅ What “good” looks like

Tracer concentration, receptor density, equilibrium assumptions, and ligand kinetics all influence whether Already available in Terry’s Corner: 30 in-depth lessons and 3 live AMAs  spanning binding, kinetics, probes, fluorescence-based assays, and why availability can matter as much as discovery itself. 🎧 Listen This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. 👉 Access this week’s full Premium Edition here ➤ Voice of the Community “It’s like being at a GPCR

. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. in real life: Meetings end with explanations, not decisions BD calls “went great,” but nothing moves From the outside, it looks like ambiguity. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus.

JB short-circuits that anxiety with a single line he’s used for years: “Hi, I’m JB. His tools exist because he constantly asks: What limitation is chemistry solving here? What limitation is biology solving? For more insight and nuance, listen to the full episode with JB. If JB's story resonates 🎧 Listen to part 1 of this series with Dr.

solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like Founders who prepare to present  often miss the deeper expectation: the FDA is not just listening, it What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. In reality, the FDA acts more like a systems-level risk assessor . indication selection to study design, should be filtered through the question: “What would this look like

. 👉 Opening with mechanisms forces the listener to do all the work. . ✅ Start with relevance, not results. 2️⃣ Using buzzwords instead of clarity Words like “platform”, Your listener doesn’t want to be impressed. If your listener doesn’t know what to do next or who should be involved, the conversation stalls. ✅ A Make it easy for the listener to understand what sets your approach apart from existing solutions or

PAMs permit enhancement without replicating the liabilities of orthosteric agonists. Endogenous ligands remain part of the signaling equation, preserving physiological patterning. Efficacy is not a molecule-only attribute—it's a joint property of ligand and system. High-coupled systems inflate apparent efficacy; low-coupled systems expose its limits. Dr. One carries broad off-target risk; the other behaves more like a high-affinity ligand with slow dissociation

GPCR signaling wasn’t linear. It wasn’t clean. shaped his partnership with JB, the chemist who would eventually help his lab visualize receptors in living They think in functional groups, fluorophores, linkers, and binding pockets. Instead of forcing antibodies to do what they weren’t built for, JB’s group engineered fluorescent ligands The signaling didn’t line up. The knockout behaved differently than expected.

. 👉 We’re talking about the type of quiet misalignment that appears to be progress but feels like confusion You assume your cofounder sees the same finish line you do. When these lines blur, so do accountability and execution. 3️⃣ The third and hardest shift is restoring Realignment as a Growth Lever, Not Just a Fix 👉 Most founders treat alignment like a hygiene issue. But because it ensures everyone is solving the same problem. ✅ If your biotech startup feels like it’

 to remotely control GPCR signaling with light. This was the moment when photopharmacology felt like the future. The literature was buzzing. Live-tissue dynamics become guesswork. This accidental tool changed that. And importantly, they liked working together. Scientific progress is rarely linear. But depth compounds.

Meanwhile, researchers in the building across the way turned off the lights at 6 PM.  vs. cell lines. They start with people you actually like working with . GPCR–islet signaling links extended beyond classical ligand models.Collaboration and long-term persistence Should patients stay on incretin therapies for life?

David Hodson walks through how his team uses fluorescence tools and chemically engineered ligands to Fluorescent ligand engineering clarifies receptor behavior that cell lines can’t reveal. Who should listen Researchers navigating complex datasets, balancing innovation with assay rigor, or Listen to the episode ➤ Quick Links Assess GPCR Biased Signaling of Agonist How GPCR Collaboration Built With live GPCR University courses returning next year and platform capabilities expanding, Premium pricing

Most labs operated like small, competing startups. That gave them capabilities others couldn’t match — from receptor biosensor platforms to live-cell imaging Weekly seminars were mandatory but lightweight, designed to connect  rather than perform. It’s a competitive advantage. 🎧 Listen to the full episode:   Leadership, Luck, and GPCR Signaling 🔓

Just her, radioactive ligands, and steady hands. Every step felt like it could make or break the result, The pace and precision of GPCR research today — from high-throughput ligand screens to real-time signaling readouts — are built on the discipline Michelle’s path wasn’t linear. Her career didn’t follow a straight line — it zigzagged through long nights, and calculated leaps.

The Moment It Clicked Once the initial spark was lit, Michelle’s curiosity snowballed. For Early-Career Scientists: Your pivotal moment might not feel like fireworks. For innovators and biotech strategists, stories like Michelle’s reveal how scientific leadership emerges For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way . 🎧 Listen to the full conversation with Michelle Halls on  The Dr.